Skip to main content
SpringerLink
Log in

Reserpine

A relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

  • Clinical Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

An Erratum to this article was published on 01 January 1992

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;141:2562–71.

    Google Scholar 

  2. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial: The Oslo Study. Am J Med. 1980;69:725–30.

    Article  PubMed  CAS  Google Scholar 

  3. Australian National Blood Pressure Study Management Committee. The Australian therapeutic trial in mild hypertension: report by the management committee. Lancet. 1980;1:1261–7.

    Google Scholar 

  4. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465–77.

    Article  Google Scholar 

  5. European Working Party on High Blood Pressure in the Elderly. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;1:1349–54.

    Google Scholar 

  6. Medical Research Council Working Party. MRC Trial of Treatment of Mild Hypertension: principal results. Br Med J. 1985;291:97–104.

    Google Scholar 

  7. Amery A. Anlauf M, Beilin LJ, et al. 1986 guidelines for the treatment of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens. 1986;4:383–6.

    Article  Google Scholar 

  8. Coope J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J. 1986;293:1146–51.

    Google Scholar 

  9. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 1986;24(suppl 1):99–118.

    Article  Google Scholar 

  10. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561–72.

    Article  PubMed  CAS  Google Scholar 

  11. Staessen J, Fagard R, Van Hoof R, Amery A. Mortality in various intervention trials in elderly hypertensive patients: a review. Eur Heart J. 1988;9:215–22.

    PubMed  CAS  Google Scholar 

  12. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY study. JAMA. 1988;259:1976–82.

    Article  PubMed  CAS  Google Scholar 

  13. 1988 Joint National Committee. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of Hypertension. Arch Intern Med. 1988;148:1023–38.

    Article  Google Scholar 

  14. Report of the British Hypertension Society Working Party. Treating mild hypertension: agreement from the large trials. Br Med J. 1989;298:694–8.

    Google Scholar 

  15. Kaplan NM. Maximally reducing cardiovascular risk in the treatment of hypertension. Ann Intern Med. 1988;109:36–40.

    PubMed  CAS  Google Scholar 

  16. Zusman RM. In defense of alternative antihypertensive therapy. Hypertension. 1988;12:327–9.

    PubMed  CAS  Google Scholar 

  17. Gallup G Jr, Cotugno HE. Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med. 1986;81(suppl 6C):20–4.

    Article  PubMed  Google Scholar 

  18. Ray WA, Schaffner W, Oates JA. Therapeutic choice in the treatment of hypertension: initial treatment of newly diagnosed hypertension and secular trends in prescribing of antihypertensive medications for Medicaid patients. Am J Med. 1986;81(suppl 6C):9–16.

    Article  PubMed  CAS  Google Scholar 

  19. Bock KD. Changing prescription patterns: impact on costs. J Hypertens. 1987;5(suppl):S83–5.

    CAS  Google Scholar 

  20. Pauly MV. The changing health care environment. Am J Med. 1986;81(suppl 6C):3–8.

    Article  PubMed  CAS  Google Scholar 

  21. Moser M. The costs of treating hypertension. Cardiovasc Drugs Ther. 1989;3:743–7.

    Article  PubMed  CAS  Google Scholar 

  22. Stason WB. Opportunities for improving the cost-effectiveness of antihypertensive treatment. Am J Med. 1986;81(suppl 6C):45–9.

    Article  PubMed  CAS  Google Scholar 

  23. Shulman NKB, Martinez B, Brogen D, Carr AA, Miles CG. Financial cost as an obstacle to hypertension therapy. Am J Public Health. 1986;76:1105–8.

    PubMed  CAS  Google Scholar 

  24. Gronvall JA. ‘Dollar Dilemma’ limits VA access. U.S. Medicine. 1990;26:14–5.

    Google Scholar 

  25. Thomas JEP. Hypertension and drug choice in the developing world. Cent Afr J Med. 1987;33:263–6.

    PubMed  CAS  Google Scholar 

  26. Moser M. “Cost containment” in the management of hypertension. Ann Intern Med. 1987;107:107–8.

    PubMed  CAS  Google Scholar 

  27. Whelton PK. Systemic hypertension, diuretic drugs, arrhythmias and death. Am J Cardiol. 1985;55:221–2.

    Article  PubMed  CAS  Google Scholar 

  28. Kaplan NM. Our appropriate concern about hypokalemia. Am J Med. 1984;77:1–4.

    Article  PubMed  CAS  Google Scholar 

  29. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;2:581–4.

    Article  Google Scholar 

  30. Anonymous. How far to lower blood pressure? Lancet. 1987;2:251–2.

  31. Freis ED. Critique of the clinical importance of diuretic-induced hypokalemia and elevated cholesterol level. Arch Intern Med. 1989;149:2640–8.

    Article  PubMed  CAS  Google Scholar 

  32. Thompson WG. An assault on old friends: thiazide diuretics under siege. Am J Med Sci. 1990;300:152–8.

    Article  PubMed  CAS  Google Scholar 

  33. O’Kelly BF, Massie BM, Tabau JF, Szlachcic J. Coronary morbidity and mortality, pre-existing silent coronary artery disease and mild hypertension. Ann Intern Med. 1989;110:1017–26.

    PubMed  CAS  Google Scholar 

  34. Moser M. Suppositions and speculations—their possible effects on treatment decisions in the management of hypertension. Am Heart J. 1989;118:1362–9.

    Article  PubMed  CAS  Google Scholar 

  35. Moser M. Commentary. Am J Med Sci. 1990;300:159–62.

    Article  Google Scholar 

  36. Multiple Risk Factor Intervention Trial Research Group. Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:16–24.

    Article  Google Scholar 

  37. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1–15.

    Article  Google Scholar 

  38. Medical Research Council Working Party on Mild to Moderate Hypertension. Ventricular extra systole during thiazide treatment: substudy of MRC mild hypertension trial. Br Med J. 1987;287:1249–53.

    Google Scholar 

  39. Hypertension Detection and Follow-up Program Cooperative Group. The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. Circulation. 1984;70:996–1003.

    Google Scholar 

  40. Papademetriou V, Notargiacomo A, Heine D, Fletcher RD, Freis ED. Effects of diuretic therapy and exercise-related arrhythmias in systemic hypertension. Am J Cardiol. 1989;64:1152–6.

    Article  PubMed  CAS  Google Scholar 

  41. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;355:827–38.

    Article  Google Scholar 

  42. Petursson SR, Wardell WM, Curran JP. National rates and patterns of consumption of antihypertensive drugs in relation to their availability in the United States, the United Kingdom, Australia and New Zealand. Ann N Y Acad Sci. 1978;304:320–30.

    Article  PubMed  CAS  Google Scholar 

  43. Tuck ML, Griffiths RF, Johnson LE, Stern N, Morley JE. Hypertension in the elderly. J Am Geriatr Soc. 1988;36:630–43.

    PubMed  CAS  Google Scholar 

  44. Applegate WB. Hypertension in elderly patients. Ann Intern Med. 1989;110:901–15.

    PubMed  CAS  Google Scholar 

  45. Tjoa HI, Kaplan NM. The treatment of hypertension in the elderly. JAMA. 1990;264:1015–18.

    Article  PubMed  CAS  Google Scholar 

  46. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 125 mm Hg. JAMA 1967;202:116–22.

    Article  Google Scholar 

  47. Veterans Administration Cooperative Study Group on antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg. JAMA. 1970;213;1143–52.

    Article  Google Scholar 

  48. Gibb WE, Malpas JS, Turner P, White RJ. Comparison of bethanidine, alpha-methyldopa, and reserpine in essential hypertension. Lancet. 1970;2:275–7.

    Article  PubMed  CAS  Google Scholar 

  49. Agnew TM, Irvine ROH, North JDK. Methyldopa and hydrochlorothiazide compared with reserpine and hydrochlorothiazide in hypertension. Br Med J. 1963;2:781–3.

    PubMed  CAS  Google Scholar 

  50. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes—results of a Department of Veterans Affairs cooperative study. Hypertension. 1990;15:348–60.

    PubMed  CAS  Google Scholar 

  51. Finnerty FA, Gyftopolous A. Berry C. McKenney A. Step 2 regimens in hypertension. JAMA. 1979;241:579–81.

    Article  PubMed  Google Scholar 

  52. Channick BJ, Kessler WB, Marks AD, Adlin EV. A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension. Clin Ther. 1981;4:175–83.

    PubMed  CAS  Google Scholar 

  53. Stein CM, Neill P, Mwaluko GMP, Kusema T. Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe. S Afr Med J. 1990;77:243–5.

    PubMed  CAS  Google Scholar 

  54. Applegate WB, Carper ER, Kahn SE, et al. Comparison of the use of reserpine versus alpha-methyldopa for second step treatment of hypertension in the elderly. J Am Geriatr Soc. 1985;33:109–15.

    PubMed  CAS  Google Scholar 

  55. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol in the treatment of essential hypertension. JAMA. 1977;237:2303–10.

    Article  Google Scholar 

  56. Seedat YK, Hoosen S, Bhigjee AI. Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in black and Indian hypertensive patients. S Afr Med J. 1984;65:915–7.

    PubMed  CAS  Google Scholar 

  57. Poulter NR, Sanderson JE. Reserpine versus beta-blocker as an additive to a diuretic in the treatment of Kenyan hypertensives. E Afr Med J. 1986;63:412–6.

    CAS  Google Scholar 

  58. Lochaya S, Jansiriskul V, Srivorpongpan R, Jiamsucson K, Suvachittanont O. Antihypertensive effects of metoprolol and reserpine-hydrochlorothiazide. J Med Assoc Thai. 1982;65:203–11.

    PubMed  CAS  Google Scholar 

  59. Ogawa K, Ban M, Ito T, et al. Diltiazem for treatment of essential hypertension: a double-blind controlled study with reserpine. Clin Ther. 1984;6:844–53.

    PubMed  CAS  Google Scholar 

  60. Participating Veterans Administration Medical Centers. Low doses v standard dose of reserpine: a randomized, double-blind, multiclinic trial in patients taking chlorthalidone. JAMA. 1982;248:2471–7.

    Article  Google Scholar 

  61. Finnerty FA. Chlorthalidone plus reserpine versus hydrochlorothiazide plus reserpine in a stepped-care approach to the treatment of essential hypertension. J Clin Pharmacol. 1980;20:357–63.

    PubMed  Google Scholar 

  62. Wandless I, Muckow JC, Smith A, et al. Compliance with prescribed medicines: a study of elderly patients in the community. J R Coll Gen Pract. 1979;29:391–6.

    PubMed  CAS  Google Scholar 

  63. Widmer RB, Cadoret RF, Troughton E. Compliance characteristics of 291 hypertensive patients from a rural Midwest area. J Fam Pract. 1983;17:619–25.

    PubMed  CAS  Google Scholar 

  64. Luxenberg J, Feigenbaum LZ. The use of reserpine for elderly hypertensive patients. J Am Geriatr Soc. 1983;31:556–9.

    PubMed  CAS  Google Scholar 

  65. Gifford RW, Williams GW, Vidt DG, Bolen K, Acker C. Duration of effect of single daily doses of reserpine and hydroflumethiazide evaluated by noninvasive technology in hypertensive patients. Cleve Clin J Med. 1982;49:209–18.

    Google Scholar 

  66. Kannel WB. Prevalence and natural history of electro-cardiographic left ventricular hypertrophy. Am J Med. 1983;75(suppl 3A):4–11.

    Article  PubMed  CAS  Google Scholar 

  67. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation. 1987;75(suppl I):116–23.

    Google Scholar 

  68. Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med. 1988;108:7–13.

    Google Scholar 

  69. Pringle SD, MacFarlane PW, McKillop JH, Lorimer AR, Dunn FG. Pathophysiologic assessment of left ventricular hypertrophy and strain in asymptomatic patients with essential hypertension. J Am Coll Cardiol. 1989;13:1377–81.

    Article  PubMed  CAS  Google Scholar 

  70. MacMahon S, Collins S, Rautahaiju P, et al., for the Multiple Risk Factor Intervention Trial Research Group. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therpy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989;63:202–10.

    Article  PubMed  CAS  Google Scholar 

  71. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. 1984;77:18–22.

    Article  PubMed  CAS  Google Scholar 

  72. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173–6.

    PubMed  CAS  Google Scholar 

  73. Kannel WB, Abbott RE. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. Am Heart J. 1986;111:391–7.

    Article  PubMed  CAS  Google Scholar 

  74. Levy D. Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60:560–5.

    Article  PubMed  CAS  Google Scholar 

  75. McLenachen JM, Henderson E, Morris RI, Dargie HJ. Ventricular arrhythmias in patients with left ventricular hypertrophy. N Engl J Med. 1987;317:787–92.

    Article  Google Scholar 

  76. Koren MJ, Devereux RB, Pappas TW, et al. Echocardiographic left ventricular mass predicts complictions of hypertension in both men and women. Am J Hypertens. 1988;1:12A.

    Google Scholar 

  77. Devereux RB. Importance of left ventricular hypertrophy mass as a predictor of cardiovascular morbidity in hypertension. Am J Hypertens. 1989;2:650–4.

    PubMed  CAS  Google Scholar 

  78. Corea L, Bentiviglio M, Verdecchia P, Providenza M, Motolese M. Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol. Int J Pharm Ther Toxicol. 1984;22:365–70.

    CAS  Google Scholar 

  79. Dunn FG, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation. 1987;76:254–8.

    PubMed  CAS  Google Scholar 

  80. Fouad FM, Nakashimi Y, Tarazi R, Salcedo E. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa: lack of association with blood pressure control. Am J Cardiol. 1982;49:795–801.

    Article  PubMed  CAS  Google Scholar 

  81. Dunn FG, Oligman W, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 1984;53:105–8.

    Article  PubMed  CAS  Google Scholar 

  82. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984;53:1044–49.

    Article  PubMed  CAS  Google Scholar 

  83. Amodeo C, Kobrin I. Ventura HO, Messerli FH, Frohlich ED. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation. 1986;73:108–13.

    PubMed  CAS  Google Scholar 

  84. Julien J, Dufloux M-A, Prasquier R, et al. Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double blind comparison. J Am Coll Cardiol. 1990;16:137–42.

    Article  PubMed  CAS  Google Scholar 

  85. Komsuoglu B, Ozgur O, Duman EL, Kumsouglu SS. The effect of chronic antihypertensive therapy on the index of left ventricular mass in patients with essential hypertension. Int J Cardiol. 1989;22:75–81.

    Article  PubMed  CAS  Google Scholar 

  86. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: 1. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–64.

    Article  Google Scholar 

  87. Gordon DJ, Knoke J, Prostfeld JZ, Superko R, Tyroler HA. High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Primary Prevention Trial. Circulation. 1986;74:1217–25.

    PubMed  CAS  Google Scholar 

  88. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA. 1990;263:1795–801.

    Article  Google Scholar 

  89. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med. 1986;80(suppl 2A):23–32.

    Article  PubMed  CAS  Google Scholar 

  90. MacMahon SW, MacDonald GJ. Antihypertensive treatment and plasma lipoprotein levels: the associations in data from a population study. Am J Med. 1986;80(suppl 2A):40–8.

    Article  PubMed  CAS  Google Scholar 

  91. Assman G, Schulte H. The prospective cardiovascular Munster study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol. 1987;59:9G-17G.

    Article  Google Scholar 

  92. Williams RR, Hunt SC, Hopkins PN. Familial dyslipidemic hypertension: evidence from 58 families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:3579–86.

    Article  PubMed  CAS  Google Scholar 

  93. Ames RP, Peacock PB. Serum cholesterol during treatment of hypertension with diuretic drugs. Arch Intern Med. 1984;144:710–4.

    Article  PubMed  CAS  Google Scholar 

  94. Weinberger MH. Antihypertensive therapy and lipids: paradoxical influences on cardiovascular disease risk. Am J Med. 1986;80(suppl 2A):64–70.

    Article  PubMed  CAS  Google Scholar 

  95. Ames RP. Antihypertensive drugs and lipid profiles. Am J Hypertens. 1988;1:421–7.

    PubMed  CAS  Google Scholar 

  96. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280–8.

    Article  PubMed  CAS  Google Scholar 

  97. Roberts WC. Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J. 1989;117:709–14.

    Article  PubMed  CAS  Google Scholar 

  98. Samuelsson O, Wilhelmsen L, Andersson OK, et al. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: results from the primary prevention trial in Göteborg, Sweden. JAMA. 1987;258:1768–76.

    Article  PubMed  CAS  Google Scholar 

  99. Grimm RH Jr, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive men. Ann Intern Med. 1981;94:7–11.

    PubMed  Google Scholar 

  100. Lasser NL, Grandits G, Caggiula AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76(2A):52–6.

    Article  PubMed  CAS  Google Scholar 

  101. Greenberg G, Brennan PJ, Miall WE. Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial. Am J Med. 1984;76(2A):45–51.

    Article  PubMed  CAS  Google Scholar 

  102. McKenney JM, Goodman RP, Wright JT Jr, Rifai N, Aycock DG, King ME. The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipoproteins. Pharmacotherapy. 1986;6:179–84.

    PubMed  CAS  Google Scholar 

  103. Ames RP. The influence of non-beta-blocking drugs on the lipid profile: are diuretics outclassed as initial therapy for hypertension? Am Heart J. 1987;114:998–1006.

    Article  PubMed  CAS  Google Scholar 

  104. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens. 1987;5:561–72.

    Article  PubMed  CAS  Google Scholar 

  105. Pollare T, Lethell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.

    Article  PubMed  CAS  Google Scholar 

  106. Foss OP, Jensen K. The effect of captopril and metoprolol as monotherapy or combined with bendroflumethiazide on blood lipids. J Intern Med. 1990;227:110–23.

    Article  Google Scholar 

  107. Ames RP, Hill P. Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol. 1982;4(suppl 2):S206–12.

    PubMed  Google Scholar 

  108. Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251:1006–8.

    Article  PubMed  CAS  Google Scholar 

  109. Muller JC, Pryor WW, Gibbons JE, Orgain ES. Depression and anxiety occurring during rauwolfia therapy. JAMA. 1955;159:836–9.

    CAS  Google Scholar 

  110. Limieux G, Davignon A, Genest J. Depressive states during rauwolfia therapy for arterial hypertension: a report of 30 cases. Can Med Assc J. 1956;74:522–6.

    Google Scholar 

  111. Quetsch RM, Achor RWP, Litin EM, Faucett RL. Depressive reactions in hypertensive patients: a comparison of those treated with rauwolfia and those receiving no specific antihypertensive treatment. Circulation. 1959;19:366–75.

    PubMed  CAS  Google Scholar 

  112. Ayd FJ. Drug-induced depression—fact or fallacy. N Y State J Med. 1958;58:354–6.

    PubMed  Google Scholar 

  113. Bernstein S, Kaufman MR. A psychological analysis of apparent depression following rauwolfia therapy. Mt Sinai J Med. 1960;27:525–30.

    Google Scholar 

  114. Goldstein G, Materson BJ, Cushman WC, et al. Treatment of hypertension in the elderly: II. Cognitive and behavioral function—results of a Department of Veterans Affairs Cooperative Study. Hypertension. 1990;15:361–9.

    PubMed  CAS  Google Scholar 

  115. Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J. 1973;3:485–90.

    Article  PubMed  CAS  Google Scholar 

  116. Moss HB, Procci WR. Sexual dysfunction associated with oral antihypertensive medication: a critical survey of the literature. Gen Hosp Psychiatary. 1982;4:121–9.

    Article  CAS  Google Scholar 

  117. Bauer GE, Baker J, Hunyor SN, et al. Side-effects of antihypertensive treatment: a placebo-controlled study. Clin Sci. 1978;55:341s-4s.

    Google Scholar 

  118. Liebowitz D, Carbone JV. Effect of varying doses of reserpine on gastric secretion. N Engl J Med. 1957;257:227–9.

    Article  PubMed  CAS  Google Scholar 

  119. Bachrach WH. Reserpine, gastric secretion, and peptic ulcer. Dig Dis Sci. 1959;4:117–23.

    Article  CAS  Google Scholar 

  120. Ferguson R, Rothenberg R, Nies A. Patient acceptance of guanethidine as therapy for mild to moderate hypertension—a comparison with reserpine. Circulation. 1976;54:32–7.

    PubMed  CAS  Google Scholar 

  121. Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer. Lancet. 1974;2:669–71.

    Google Scholar 

  122. Armstrong B, Stevens N, Doll R. Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet. 1974;2:672–5.

    Article  PubMed  CAS  Google Scholar 

  123. Heinonen OP, Shapiro S, Tuominen L, Turunen MI. Reserpine use in relation to breast cancer. Lancet. 1974;2:675–7.

    Article  PubMed  CAS  Google Scholar 

  124. Mack TM, Henderson BE, Gerkins VR, Baptista J, Pike MC. Reserpine and breast cancer in a retirement community. N Engl J Med. 1975;292:1366–71.

    Article  PubMed  CAS  Google Scholar 

  125. O’Fallon WM, Labarthe DR, Kurland LT. Rauwolfia and derivatives and breast cancer: a case/control study in Olmsted County, Minnesota. Lancet. 1975;2:292–6.

    Article  PubMed  CAS  Google Scholar 

  126. Laska EM,Siegel C, Meisner M, Fischer S, Wanderling J. Matched-pairs study of reserpine use and breast cancer. Lancet. 1975;2:296–300.

    Article  PubMed  CAS  Google Scholar 

  127. Lilienfeld AM, Chang L, Thomas DB, Levin ML. Rauwolfia derivatives and breast cancer. Johns Hopkins Med J. 1976;139:41–50.

    PubMed  CAS  Google Scholar 

  128. Armstrong B, Skegg D, White G, Doll R. Rauwolfia derivatives and breast cancer in hypertensive women. Lancet. 1976;2:8–12.

    Article  PubMed  CAS  Google Scholar 

  129. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Idanpaan-Heikkila J. Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer. 1976;18:727–38.

    Article  PubMed  CAS  Google Scholar 

  130. Kewitz H, Jesdinsky HJ, Schroter PM, Lintner E. Reserpine and breast cancer in women in Germany. Eur J Clin Pharmacol. 1977;11:79–83.

    Article  PubMed  CAS  Google Scholar 

  131. Christopher LJ, Crooks J, Davidson JF, et al. A multicentre study of rauwolfia derivates and breast cancer. Eur J Clin Pharmacol. 1977;11:409–17.

    Article  PubMed  CAS  Google Scholar 

  132. Williams RR, Feinleib M, Connor RJ, Stegens JL. Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Natl Cancer Inst. 1978;61:327–35.

    PubMed  CAS  Google Scholar 

  133. Kodlin D, McCarthy N. Reserpine and breast cancer. Cancer. 1978;41:761–8.

    Article  PubMed  CAS  Google Scholar 

  134. Labarthe DR, O’Fallon M. Reserpine and breast cancer: a community-based longitudinal study of 2,000 hypertensive women. JAMA. 1980;243:2304–10.

    Article  PubMed  CAS  Google Scholar 

  135. Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the Hypertension Detection and Follow-up Program. Hypertension. 1982;4:307–11.

    PubMed  CAS  Google Scholar 

  136. Cooper JK, Love DW, Raffoul PR. International prescription non-adherence (noncompliance) by the elderly. J Am Geriatr Soc. 1982;30:329–33.

    PubMed  CAS  Google Scholar 

  137. Kendrick R, Bayne JRD. Compliance with prescribed medication by elderly patients. Can Med Assoc J. 1982;127:961–2.

    PubMed  CAS  Google Scholar 

  138. Morrow D, Leirer V, Sheikh J. Adherence and medication instructions: review and recommendations. J Am Geriatr Soc. 1988;36:1147–60.

    PubMed  CAS  Google Scholar 

  139. Kazis LE, Friedman RH. Improving medication compliance in the elderly: strategies for the health care provider. J Am Geriatr Soc. 1988;36:1161–2.

    PubMed  CAS  Google Scholar 

  140. Peck CL, King NJ. Increasing patient compliance with prescriptions. JAMA. 1982;248:2874.

    Article  PubMed  CAS  Google Scholar 

  141. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881–4.

    Article  PubMed  CAS  Google Scholar 

  142. Parker M, Atkinson J. Withdrawal syndromes following cessation of treatment with antihypertensive drugs. Gen Pharmacol. 1982;13:79–85.

    PubMed  CAS  Google Scholar 

  143. 1991 Drug Topics Red Book, Oradell, NJ: Medical Economics Company, 1991.

Download references

Author information

Authors and Affiliations

  1. Division of General Medicine (111-P), Veterans Affairs Medical Center, 3710 U.S. Veterans Road, P.O. Box 1034, 97207, Portland, OR

    Gregory J. Magarian MD

Authors
  1. Gregory J. Magarian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Received from the Department of Medicine, Oregon Health Sciences University, and the Division of General Internal Medicine, Veterans Affairs Medical Center, Portland, Oregon.

An erratum to this article is available at http://dx.doi.org/10.1007/BF02599123.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magarian, G.J. Reserpine. J Gen Intern Med 6, 561–572 (1991). https://doi.org/10.1007/BF02598229

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02598229

Keywords

Search

Navigation